Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| XENON PHARMACEUTICALS | 19 | - | +47,22 % | ||
| DYNE THERAPEUTICS | 11 | - | +15,33 % | ||
| REGENERON PHARMACEUTICALS | 8 | 22 | +1,68 % | ||
| ARS PHARMACEUTICALS | 6 | - | +1,05 % | ||
| EDITAS MEDICINE | 5 | - | +22,14 % | ||
| OLEMA PHARMACEUTICALS | 5 | - | -22,35 % | ||
| INCYTE | 4 | 25 | -0,82 % | ||
| BIONTECH | 4 | 13 | -0,46 % | ||
| UNITED THERAPEUTICS | 4 | 8 | +9,25 % | ||
| LYELL IMMUNOPHARMA | 4 | 8 | +14,38 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:42 | What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? | 3 | Benzinga.com | ||
| 18:36 | Regeneron-Licensed Obesity Drug Olatorepatide Shows Positive Results In Phase 3 Trial | 105 | AFX News | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals said olatorepatide, an investigational obesity treatment it licensed from Hansoh Pharmaceutical Group, delivered positive Phase 3 trial results... ► Artikel lesen | |
| 18:30 | Baird raises Xenon Pharmaceuticals price target to $97 on trial data | 1 | Investing.com | ||
| 18:30 | Baird reiterates Dyne Therapeutics stock rating on trial progress | 1 | Investing.com | ||
| 18:29 | Regeneron-Licensed Obesity Drug Olatorepatide Shows Positive Results In Phase 3 Trial | 3 | RTTNews | ||
| 18:10 | TD Cowen bestätigt Kaufempfehlung für Editas Medicine nach Pipeline-Fortschritten | 3 | Investing.com Deutsch | ||
| 18:10 | H.C. Wainwright senkt Kursziel für Olema Pharmaceuticals nach Studiendaten | 5 | Investing.com Deutsch | ||
| 18:06 | TD Cowen reiterates Editas Medicine stock Buy rating on pipeline progress | 1 | Investing.com | ||
| 18:06 | H.C. Wainwright cuts Olema Pharmaceuticals price target on trial data | 1 | Investing.com | ||
| 17:59 | Xenon Pharmaceuticals Shares Surge 48% On Strong Phase 3 Epilepsy Trial Results | - | RTTNews | ||
| 17:54 | Jones Trading reiterates Buy on Dyne Therapeutics stock after DMD, DM1 updates | 1 | Investing.com | ||
| 17:46 | UniQure leads genetic medicine biotech rally after news of Prasad's exit | 2 | BioPharma Dive | ||
| 17:46 | Aktie von Oric Pharmaceuticals bricht nach Rückzug von Tazverik ein | 1 | Investing.com Deutsch | ||
| 17:42 | Stifel reiterates Dyne Therapeutics stock rating on trial design | 1 | Investing.com | ||
| 17:34 | Cytokinetics auf Leerink-Konferenz: Strategischer Wachstumskurs in der Kardiologie | 1 | Investing.com Deutsch | ||
| 17:34 | Veracyte auf der Leerink Global Healthcare Konferenz: Strategischer Fokus auf profitables Wachstum | 1 | Investing.com Deutsch | ||
| 17:30 | Why Is Olema Pharmaceuticals Stock Dropping On Monday? | 1 | Benzinga.com | ||
| 17:10 | Dyne-Aktie: Positive Studiendaten zu Muskeldystrophie stärken laut Jones den Ausblick | 1 | Investing.com Deutsch | ||
| 17:06 | A Peek at Esperion Therapeutics' Future Earnings | 13 | Benzinga.com | ||
| 17:06 | Dyne stock looks stronger after muscular dystrophy data, says Jones | 1 | Investing.com |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.